Manager
G.I.I.C. FINECO, S.A., S.G.I.I.C.
See the CNMV manager universe →
Fund page
FINECO INVESTMENT OFFICE, FI
Category
—
Latest period
H2 2025
Positions
136
Portfolio as of 2025-12-31. Source: periodic filing with the CNMV. View original filing (PDF)
Full portfolio
Every position in the latest periodic filing, largest weight first. Aggregates ("other equities...") are baskets of small positions the filing itself does not break out line by line.
136
Company
Type
Country
Weight
Price
This period's moves
H2 2025 vs H1 2025 (estimated)
New: 26
Exits: 24
Increases: 2
Cuts: 1
+ Acciones|TEVA PHARMACEUTICALS NE
Enters the portfolio at 0.09% weight.
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
View company page →− U. S. TREASURY
Leaves the portfolio; it was 2.34% of weight.
− ESTADO ALEMAN
Leaves the portfolio; it was 1.58% of weight.
− UNITED MEXICAN STATE
Leaves the portfolio; it was 0.79% of weight.
− Acciones|AIA GROUP
Leaves the portfolio; it was 0.18% of weight.
− Acciones|TEXAS INSTRUMENTS INC
Leaves the portfolio; it was 0.18% of weight.
− Acciones|ARM HOLDINGS PLC
Leaves the portfolio; it was 0.17% of weight.
− Acciones|HEINEKEN NV
Leaves the portfolio; it was 0.14% of weight.
Heineken N.V. brews and sells beer and cider in Europe, the Americas, Africa, the Middle East, and the Asia Pacific. The company also provides soft drinks. It sells its products under the Heineken, Heineken 0.0, Heineken Silver, Amstel, Moretti, Tiger, Desperados, Edelweiss, Lagunitas, Orchard Thieves, Windhoek, Dos Equis, Red Stripe, Kingfisher, Bintang, Gosser, Affligem, Mort Subite, Strongbow, Stassen, Bulmers, Old Mout, Savanna, Turbo King, Tecate, Lagunitas Hoppy Refresher, Bia Viet, Tiger Crystal, Birra Moretti, Harar, Cruzcampo, Bernini, Legend Stout, Beavertown, Stëlz, Texels, Ladrón, Bandida, Stibitzer, El Aguila, and Murphy's brands. In addition, the company engages in rental of pubs and bars; wholesale activities; and pub management and technical services. The company offers its products to retailers, wholesalers and distributors, bars, restaurants, clubs, cafes, and hotels. Heineken N.V. was incorporated in 1864 and is headquartered in Amsterdam, the Netherlands. Heineken N.V. is a subsidiary of Heineken Holding N.V.
View company page →− Acciones|FORTINET INC
Leaves the portfolio; it was 0.14% of weight.
− Acciones|PNC FINANCIAL SERVICES
Leaves the portfolio; it was 0.13% of weight.
− Acciones|VERISIGN INC
Leaves the portfolio; it was 0.12% of weight.
− Acciones|KEYENCE CORP
Leaves the portfolio; it was 0.12% of weight.
− Acciones|COMPAGNIE FIN ET INDUS
Leaves the portfolio; it was 0.11% of weight.
Compagnie de Saint-Gobain S.A., together with its subsidiaries, designs, manufactures, and distributes materials and solutions for the construction and industrial markets worldwide. It operates in five segments: High Performance Solutions; Northern Europe; Southern Europe Middle East (ME) Americas; and Asia-Pacific. The company offers plaster-based products and systems for the construction and renovation markets under the Placo, Rigips, and Gyproc brands; insulation solutions for a range of applications, such as heating and air conditioning systems, insulation of pipes in industrial installations, engine and interior compartments of vehicles, household appliances, and photovoltaic panels under the Isover, CertainTeed, and Izocam brands; and mortars and construction chemicals under the Weber, Chryso, and GCP brands. It also provides ceilings under the Ecophon, CertainTeed, Eurocoustic, Gyptone, and Vinh Tuong brands; glazing solutions for buildings and mobility, including flat glass under the Saint-Gobain Glass, GlassSolutions, Vetrotech, and SageGlass brands; ductile cast iron pipe systems, covers, and gratings under the PAM brand; glass fiber materials and technical textiles; and abrasives, adhesives, sealants, adhesive tapes, foams, and films. In addition, the company offers ceramics and polymers; and exterior products comprising asphalt and composite shingles, solar roofing solutions, roll roofing systems, accessories, polymer shakes and shingles, and insulation cladding solutions under the CertainTeed brands. Further, it distributes heavy building materials; plumbing, heating, ventilation, and sanitaryware products; construction products; office partitions; timber and byproducts; home improvement products and services; bathrooms and kitchens; steel; and site equipment, PPEs, and tools. Compagnie de Saint-Gobain S.A. was founded in 1665 and is headquartered in Courbevoie, France.
View company page →− Acciones|GARTNER INC
Leaves the portfolio; it was 0.11% of weight.
− Acciones|INTL BUSINESS MACHINES CORP
Leaves the portfolio; it was 0.11% of weight.
− Acciones|WALLMART
Leaves the portfolio; it was 0.10% of weight.
− Acciones|UNILEVER NV-CVA
Leaves the portfolio; it was 0.10% of weight.
− Acciones|GLAXOSMITHKLINE
Leaves the portfolio; it was 0.10% of weight.
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, inflammation, and inhaled medicines for HIV, respiratory eosinophildriven diseases, lupus and lupus nephritis, ovarian cancer, and endometrial cancer. It also provides vaccines for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus, Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella and Chickenpox, and Human Papilloma Virus. Additionally, the company offers general medicines for asthma, COPD, bacterial infection, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. It also focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. It has a collaboration agreement with CureVac to develop mRNA vaccines for infectious diseases; and strategic research collaboration with Engitix Ltd. to identify and validate novel therapeutic targets driving liver fibrosis regression. The company has a strategic alliance with AN2 Therapeutics, Inc. for the development of new therapies for TB. GSK plc was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. The company was founded in 1715 and is headquartered in London, United Kingdom.
View company page →− Acciones|CARRIER GLOBAL CORP
Leaves the portfolio; it was 0.08% of weight.
− Acciones|COSTCO WHOLESALE CORP
Leaves the portfolio; it was 0.07% of weight.
− Acciones|SMC CORP
Leaves the portfolio; it was 0.07% of weight.
− Acciones|FAIR ISAAC CORP
Leaves the portfolio; it was 0.07% of weight.
− Acciones|NUTRIEN LTD
Leaves the portfolio; it was 0.05% of weight.
Nutrien Ltd. provides crop inputs and services. The company operates through four segments: Retail, Potash, Nitrogen, and Phosphate. The Retail segment markets crop nutrients, crop protection products, seed, and merchandise, as well as provides agronomic application and financing services and solutions; and produces proprietary products, including proprietary crop nutrient, crop protection, and seed products. The Potash segment includes mining and processing of potash. The Nitrogen segment owns and operates ammonia production facilities that offers ammonia, urea, ammonium nitrate (UAN), urea solutions, nitric acid, and ammonium nitrate, as well as environmentally smart nitrogen and ammonium sulfate. The Phosphate segment manufactures and sells solid and liquid phosphate fertilizers, phosphate feed, and purified phosphoric acid, which is used in feed and industrial products. The company was incorporated in 2017 and is headquartered in Saskatoon, Canada.
View company page →− Acciones|MEITUAN CLASS B
Leaves the portfolio; it was 0.05% of weight.
− Acciones|KLA CORP
Leaves the portfolio; it was 0.05% of weight.
Fixed income
Declared FI exposure
2.4 M €
% of portfolio
2.2%
Positions
3
Issuers
2
Sovereign: 1.6 M €
Corporate: 736,030 €
Maturity ladder
Observed contractual maturity of each position, repos excluded. Matured/≤3 months includes bonds maturing in the first days after the period close.
Matured or ≤3 months · 31.3%5-10 years · 32.3%> 10 years · 36.4%
Maturity
Positions
Exposure
%
Matured or ≤3 months
1
736,030 €
31.3%
3-6 months
0
0 €
0.0%
6-12 months
0
0 €
0.0%
1-2 years
0
0 €
0.0%
2-5 years
0
0 €
0.0%
5-10 years
1
759,414 €
32.3%
> 10 years
1
855,596 €
36.4%
Unknown
0
0 €
0.0%
Top issuers
The 10 issuers with the largest declared exposure in this fund, repos excluded.
Issuer
Type
ISINs
Exposure
Next maturity
Bundesrepublik Deutschland
Sovereign
2
1.6 M €
2033-02-15
UNITED MEXICAN STATE
Corporate
1
736,030 €
2026-01-08
Top instruments
The 10 instruments with the largest declared exposure. No yield, IRR or rating: there's no reliable data to compute them.
ISIN
Coupon
Maturity
Exposure
DE0001102614 Bundesrepublik Deutschland
1.80%
2053-08-15
855,596 €
DE000BU2Z007 Bundesrepublik Deutschland
2.30%
2033-02-15
759,414 €
MXBIGO000X35 UNITED MEXICAN STATE
50.00%
2026-01-08
736,030 €
Currencies
Fixed-income exposure by instrument currency.
Currency
Exposure
%
EUR
1.6 M €
68.7%
MXN
736,030 €
31.3%
This period's fixed-income moves
Compares the current fixed-income portfolio with the previous period, by ISIN. An exit that coincides with maturity isn't a sale: the bond reached its contractual date.
New positions: 1
Exits at maturity: 2
Exits not explained by maturity: 1
+ UNITED MEXICAN STATE
Enters the portfolio at 0.70% weight.
− ESTADO ALEMAN
Leaves the portfolio; it was 1.58% of weight.
◦ U. S. TREASURY
Leaves the portfolio; it was 2.34% of weight.
◦ UNITED MEXICAN STATE
Leaves the portfolio; it was 0.79% of weight.
Disclaimer
This is not financial advice. The portfolio comes from the periodic report the fund files with the CNMV and lags the real close of the period: it is a snapshot of the end of each half-year, not a real-time portfolio.